Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the consensus estimates.
Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers
Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler stocking decisions.
Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?
Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.
Eli Lilly Stock Tumbles After Disappointing Obesity Drug Sales
Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by wholesale distributors hurt sales of its diabetes drug Mounjaro and anti-obesity medicine Zepbound.
Eli Lilly Earnings Have Wall Street Jittery on Zepbound Sales. What Comes Next.
One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from Eli Lilly and Novo Nordisk will be insatiable. That hope has added hundreds of billions of dollars to the market values of Lilly and Novo,
Lilly's third-quarter earnings and sales fall short of expectations
October 30, 2024. More for You
Eli Lilly Misses Q3 Targets, Lowers Full-Year Outlook on Weak Zepbound, Mounjaro Sales
Eli Lilly reported third-quarter earnings and revenue below Wall Street expectations, reducing its full-year adjusted profit outlook. The pharmaceutical company cited weaker sales of its weight loss drug,
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook observed through 1H24. Read more here.
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Even with this partial rebound, Lilly's share price remains roughly 13% below the peak set in late August. Some investors ...
Is Eli Lilly Stock a Buy?
However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...
The Associated Press - Business News on MSN5d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Are Eli Lilly's Lowered Expectations a Reason to Sell?
Eli Lilly reported third-quarter results before the market opened on Wednesday. Management missed Wall Street estimates and lowered earnings guidance for 2024. Sales of Zepbound and Mounjaro hardly ...
Eli Lilly had a strong Q3, so why is its stock falling?
Eli Lilly's Q3 results show strong sales growth, especially in its Mounjaro and Zepbound franchises, but lowered 2024 outlook ...
Three Buys and a Bail: Microsoft, Eli Lilly, Peloton, and Snap
Gina Sanchez, Lido Advisors chief market strategist, joins CNBC's 'The Exchange' to discuss these stocks: Microsoft, Eli ...
Stock market today: Nasdaq edges back from its record as chip companies and Eli Lilly slump
U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company ...
Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
LLY had $11.4 billion in revenue for the quarter (up 20% versus Q3 figures from last year), with a net income of $970 million ...
Yahoo Finance4h
Eli Lilly teams up with Saudi hospital to advance Alzheimer’s care
Eli Lilly Saudi Arabia and King Faisal Specialist Hospital & Research Centre (KFSHRC) have teamed up to make KFSHRC’s Neuroscience Centre a top regional hub for Alzheimer’s disease treatment. Part ...